$EYPT 0.49 Noisy

Notable posts

• @wallstengine mixed 36 eng

  $EYPT PHASE 3 TRIAL MISSES PRIMARY ENDPOINT EyePoint said its Phase 3 LUGANO trial for DURAVYU in wet AMD failed to meet the primary endpoint of non-inferiority versus aflibercept in the full dataset. The company said the miss was driven by 9 of 211 patients who had vision loss unrelated to wet AMD. Excluding those patients in an ad hoc analysis, DURAVYU met non-inferiority. DURAVYU also reduced treatment burden by 42%, with patients receiving about two fewer injections through Week 56. Results from the second pivotal Phase 3 trial, LUCIA, are expected in Q4 2026.

  view on X →
• @StockOptionCole bullish 22 eng

  Someone just desperately bought $350K of $EYPT 9/18 20C calls in minutes That's 38%+ OTM https://t.co/bFuUJ9S2J5

  view on X →
• @TENETTRADEGROUP neutral 15 eng

  Tenet Pre-Market Movers August.17.26 $OABI $ARGX $DSX $MESO $HTHT $HIVE $KEEL $HCM $SNDK $BE $SKHY $ETSY $ONTO $MU $EYPT $GLOB $ENVX $GNK $ALH $BALY $GEMI $RPD $MOVE @ripster47 | @tenet_research | @TenetCharts https://t.co/ONvDLNfD8H

  view on X →